| · Sub | Substitute for form 1449B/PTO | | | | Complete if Known | | |
|-------|-----------------------------------|---|----|-----|------------------------|---------------------------------|--|
| | | | | | Application Number | 09/554,960 | |
| l IN | INFORMATION DISCLOSURE | | | | Filing Date | February 12, 2003 | |
| S | STATEMENT BY APPLICANT | | | ANT | First Named Inventor | Kaslow, David C. | |
| | | | | | Art Unit | 1632 | |
| | (Use as many sheets as necessary) | | | | Examiner Name | Licto, Louis D. Anne-Marie Falk | |
| She | et | 1 | of | 1 | Attorney Docket Number | 015280-342100US | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------|---|--------------------------------|-----------------------------|---|
| Examiner Initials* | Cite No.1 | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or | Pages, Columns, Lines, Where |
| tititata | 140. | Number Kind Code ^{2 (F known)} | MM-DD-FFFF | Applicant of Cited Document | Relevant Passages or Relevant Figures Appear |

| | FOREIGN PATENT DOCUMENTS | | | | | | | |
|-----------|--------------------------|-------------------------|---------------------|------------------------------|------------------|--|---|----------------|
| Examiner | | Foreign Patent Document | | | Publication Date | Name of Patentee or | Pages, Columns, Lines, | |
| Initials* | No.' | Country | Number ⁴ | Kind Code ⁵ // | MM-DD-YYYY | Applicant of Cited Document | Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| AMF | 1 | wo | 89/10936 | A1 | 11-16-1989 | The United States of America as represented by the Secretary, U.S. Department of Commerce | | |
| | 2 | wo | 94/01552 | A1 | 01-20-1994 | The United States of America, as represented by the Secretary of the Department of Health and Human Services | | |
| | 3 | wo | 94/28930 | A1 | 12-22-1994 | Virogenetics Corporation | | |
| Ψ | 4 | wo | 95/08631 | A2 | 03-30-1995 | The Government of the United States of America, represented by the Secretary of the Department of Heath and Human Services | | |
| AMF | 5 | wo | 98/14472 | A1 | 04-09-1998 | The Government of the United States of America as represented by the Secretary, Department of Heath and Human Services | | |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|--------------|---|-----|--|--|
| Examiner Initials * | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T 2 | | |
| AMF | 6 | AGABIAN N., et al., "Molecular strategies of parasitic invasion," Alan R. Liss, Inc., (1987), see MENDIS, K. et al., "Immune modulation of parasite transmission in <i>Plasmodium vivax</i> malaria: Anti-gamete antibodies can both block and enhance transmission"; Molecular Strategies of Parasitic Invasion; pp. 417-426, 1987. Alan R. Liss, Inc. | | | |
| AMF | 7 | PREMAWANSA, S. et al., "Target antigens of transmission blocking immunity of <i>Plasmodium vivax</i> malaria: Characterization and polymorphism in natural parasite isolates"; <u>J. Immunol.</u> Vol. 144 (11), pp. 4376-4383 (June 1, 1990) | | | |
| AMF | 8 | SNEWIN, V. et al., "Transmission blocking immunity in <i>Plasmodium vivax</i> malaria: Antibodies raised against a peptide block parasite development in the mosquito vector"; <u>J. Exp. Med.</u> , Vol. 181, pp. 357-362 (January 1995) | | | |

| | | | |
|-----------------------|-------------------|--------------------|------------|
| Examiner Signature | /Anne Marie Falk/ | Date Considered | 01/08/2007 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.